![](https://www.demerx.com/wp-content/uploads/2022/12/hexagon.png)
What we do ?
DemeRx is a clinical stage drug development company advancing two molecules for the treatment of substance use disorders
![](https://www.demerx.com/wp-content/uploads/2022/12/Noribogaine.png)
ibogaine is a lead molecule currently in clinical trials in the UK. The clinical program is funded by a joint venture agreement with atai Life Sciences.
![](https://www.demerx.com/wp-content/uploads/2022/12/Noribogaine.png)
![](https://www.demerx.com/wp-content/uploads/2022/12/Noribogaine.png)
![](https://www.demerx.com/wp-content/uploads/2022/12/Noribogaine.png)
noribogaine is the active metabolite of ibogaine and is a new chemical entity with robust patents for multiple therapeutic indications. Our current focus is for relapse prevention in alcohol use disorder.